PREVENT-GUNCT05920343
VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy
StatusRecruiting
PhasePhase 2/3
Primary completion (estimated)
At risk: Primary completion moved at least 1 year 7 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 5 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Oct 2026 to Jun 2028
- Eligibility criteria expanded, about 19 words
- Study sites: 1 to 3
- Secondary endpoints: details revised at 3 of 4 entries
- Notable Trial status: Not Yet Recruiting to Recruiting
- Primary and study completion dates: Feb 2026 to Oct 2026
- Start date changed from estimate of Feb 2024 to Nov 4, 2024
- Study sites: 0 to 1
- Notable Start date: Sep 2023 to Feb 2024
- Primary and study completion dates: Sep 2025 to Feb 2026
- Notable Primary endpoint revised
- Secondary endpoints revised (4)
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Feasibility of enrollment, assesed by the number of patients accrued per month
Timeframe: Enrollment
Secondary (4)
Adherence to the study intervention, assessed as the proportion of patients taking the study medication >80% of days taken during the study period,
Recruitment rate
VTE incidence
Bleeding incidence
Arms and interventions
RivaroxabanExperimental
Participants receiving study drug (Rivaroxaban)
ControlPlacebo comparator
Participants receiving matched placebo
Drugs: Rivaroxaban 10 MG
Other: Placebo control
Sites
3 sites in 1 country